The COVID-19 pandemic highlights a need for the rapid development of detection strategies and assays for novel pathogens. The SARS-CoV-2 NGS Assay is a highly sensitive nucleic acid hybridization capture-based assay that detects the SARS-CoV-2 viral genome. This FDA-authorized-under-emergency-use assay combines virus-specific panels and comprehensive data analysis software and reporting capabilities to provide researchers with information on genetic variants, clade-associated variants, and phylogenetics. In this webinar brought to you by Twist Bioscience, Kristin Butcher and Mara Cuoto-Rodriguez will demonstrate the SARS-CoV-2 NGS assay technology and describe how researchers use it to detect and identify novel variants of the SARS-CoV-2 virus.
Topics to be covered
The end-to-end SARS-CoV-2 NGS assay workflow
The benefits of hybrid-capture technology and COVID-DX software
How Biotia’s COVID-DX pipeline determines the presence or absence of SARS-CoV-2, identifies genetic variants, estimates viral clades, and generates phylogenetic trees
Thursday, May 20, 2021
12:00 - 1:30 PM Eastern Time
Meet the speakers
Kristin Butcher
Senior Scientist Twist Bioscience
Mara Couto-Rodriguez Director of Research and Development Biotia
Sponsored by
Register Now
Optimizing Fluorescence-Activated Cell Sorting April 26, 2021
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
